Skip to main content

Advertisement

Table 2 Patient and tumor characteristics in relation to coexistence of AD or HS

From: Autoimmune diseases and hypersensitivities improve the prognosis in ER-negative breast cancer

  AD HS Non-hypersensitive All
Number of cases 125 72 1508 1705
Age at diagnosis of BC Median (range) 60.6 (31.5-80.4) 53.3 (25.4-82.5) 56.1 (23.6-89.5) 56.3 (23.6-89.5)
BMI Median 24.6 24.1 24.2 24.2
Age at menarche Median 13.0 13.0 13.5 13.5
Age at menopause Median 50.0 50.0 50.0 50.0
Deceased Yes 57 (46%) 30 (42%) 826 (55%) 913 (54%)
T-stage In situ 4 (3%) 5 (7%) 71 (5%) 80 (5%)
  1 68 (54%) 36 (50%) 744 (49%) 848 (50%)
  2 40 (32%) 23 (32%) 539 (36%) 602 (35%)
  3 9 (7%) 8 (11%) 104 (7%) 121 (7%)
  4 0 (0%) 0 (0%) 7 (1%) 7 (0.4%)
  Unknown 4 (3%) 0 (0%) 43 (3%) 47 (3%)
N-stage 0 54 (43%) 39 (54%) 631 (42%) 724 (43%)
  1 44 (35%) 20 (28%) 514 (34%) 578 (34%)
  2 17 (14%) 8 (11%) 204 (14%) 229 (13%)
  3 5 (4%) 4 (6%) 91 (6%) 100 (6%)
  Unknown 5 (4%) 1 (1%) 68 (5%) 74 (4%)
M-stage 0 117 (94%) 71 (99%) 1349 (90%) 1537 (90%)
  1 1 (1%) 0 (0%) 24 (2%) 25 (2%)
  Unknown 7 (6%) 1 (1%) 135 (9%) 143 (8%)
ER Status Negative 20 (16%) 17 (24%) 321 (21%) 358 (21%)
  Positive 70 (56%) 33 (46%) 664 (44%) 767 (45%)
  Unknown 35 (28%) 22 (31%) 523 (35%) 580 (34%)
Postmenopausal No 32 (26%) 31 (43%) 490 (33%) 553 (32%)
  Yes 86 (69%) 39 (54%) 936 (62%) 1061 (62%)
  Unknown 7 (6%) 2 (3%) 82 (5%) 91 (5%)
Screening No 78 (62%) 31 (43%) 934 (62%) 1043 (61%)
  Yes 29 (23%) 18 (25%) 274 (18%) 321 (19%)
  Unknown 18 (14%) 23 (32%) 300 (20%) 341 (20%)
OCP ever-use Yes 50 (40%) 42 (58%) 625 (41%) 717 (42%)
HRT ever-use Yes 31 (25%) 12 (17%) 277 (18%) 320 (19%)
Parity 0 28 (22%) 15 (21%) 250 (17%) 293 (17%)
  1 20 (16%) 15 (21%) 284 (19%) 319 (19%)
  2 56 (45%) 23 (32%) 579 (38%) 658 (39%)
  3 18 (14%) 10 (14%) 280 (19%) 308 (18%)
  4 + 3 (2%) 9 (13%) 115 (8%) 127 (7%)